<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997268</url>
  </required_header>
  <id_info>
    <org_study_id>P-13-009</org_study_id>
    <nct_id>NCT01997268</nct_id>
  </id_info>
  <brief_title>The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sancilio and Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sancilio and Company, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of SC401B (ethyl esters of&#xD;
      eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] 2 (~1260 mg EPA+DHA), 4 (~2520 mg&#xD;
      EPA+DHA) or 6 (~3780 mg EPA+DHA) capsules per day in subjects with hypertriglyceridemia&#xD;
      (triglyceride [TG] ≥500 mg/dL and ≤ 2,000 mg/dL). SC401B capsules also contain certain&#xD;
      surfactants that may aid in the absorption of EPA and DHA. Based on the results of&#xD;
      pharmacokinetic studies of healthy human subjects, unlike Lovaza®, EPA and DHA in SC401B are&#xD;
      bioavailable in both the fasted and fed states.&#xD;
&#xD;
      The protocol specified primary endpoint is the difference from the placebo group in the&#xD;
      percent change in TG concentration from baseline to week 12 for groups receiving 2, 4, or 6&#xD;
      capsules of SC401B per day. The protocol specified secondary endpoints include percent&#xD;
      changes from baseline to week 12 for total cholesterol (TC), LDL-cholesterol (LDL-C),&#xD;
      HDL-cholesterol (HDL-C), and non-HDL-cholesterol (non-HDL-C). Additional exploratory&#xD;
      variables include VLDL-cholesterol (VLDL-C), LDL-cholesterol particle size, apolipoprotein&#xD;
      (Apo) A1, Apo B, Apo C-III, and lipoprotein-associated phospholipase A2 (Lp-PLA2).&#xD;
&#xD;
      An additional objective is to determine the tolerability and safety of SC401B 2, 4 and 6&#xD;
      capsules per day for 12 weeks. Adverse events for SC401B and placebo including burping, fishy&#xD;
      taste, upset stomach, loose stools, stools with fishy smell or any other self-reported&#xD;
      observations will be evaluated. Additional safety measures will include changes in liver&#xD;
      enzymes (AST/ALT) occurring from baseline to week 12 for groups receiving 2, 4, and 6&#xD;
      capsules of SC401B and placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never initiated. IND placed on Hold&#xD;
  </why_stopped>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Serum Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment (12 weeks) in triglyceride levels between placebo and 2, 4, and 6 capsules per day of SC401B.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Severe Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 6 capsules (1.24 g each) daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC401B 2 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC401B 4 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC401B 6 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC401B 6 capsules (1.24 g each) daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corn Oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC401B 2 capsules</intervention_name>
    <arm_group_label>SC401B 2 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC401B 4 capsules</intervention_name>
    <arm_group_label>SC401B 4 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC401B 6 capsules</intervention_name>
    <arm_group_label>SC401B 6 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be male or female, age 18 years&#xD;
&#xD;
          -  Have a TG level ≥500 mg/dL and ≤2,000 mg&#xD;
&#xD;
          -  Have the ability to understand the requirements of the study and be willing to provide&#xD;
             written informed consent (as evidenced by signature on an informed consent document&#xD;
             approved by an Institutional Review Board [IRB]) and agree to abide by the study&#xD;
             restrictions and return for the required assessments.&#xD;
&#xD;
          -  Be normally active and in good health on the basis of medical history.&#xD;
&#xD;
          -  Willing to maintain a stable diet and not alter their physical activity level&#xD;
             throughout the study.&#xD;
&#xD;
          -  Women of childbearing potential must be willing to use accepted birth control methods&#xD;
             throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, planning to become pregnant, or breastfeed during the study&#xD;
             period&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 9.5% (subjects with diabetes mellitus will be required to receive&#xD;
             stable therapy)&#xD;
&#xD;
          -  History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary&#xD;
             vascularization within 6 months before screening&#xD;
&#xD;
          -  Thyroid-stimulating hormone &gt; 1.5 x upper limit of normal; clinical evidence of&#xD;
             hypothyroidism or thyroid hormonal therapy that has not been stable for&#xD;
&#xD;
               -  6 weeks before screening&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 x upper limit&#xD;
             of normal&#xD;
&#xD;
          -  An unexplained creatine kinase concentration &gt; 3 x upper limit of normal or creatine&#xD;
             kinase elevation due to known muscle disease (e.g., polymyositis, mitochondrial&#xD;
             dysfunction)&#xD;
&#xD;
          -  Blood donation of ≥1 pint within 30 days before screening or plasma donation within 7&#xD;
             days before screening&#xD;
&#xD;
          -  The consumption of &gt;2 alcoholic beverages per day after screening; a history of&#xD;
             illicit drug use within 1 year before screening&#xD;
&#xD;
          -  A history of symptomatic gallstone disease unless treated with cholecystectomy&#xD;
&#xD;
          -  Known nephrotic syndrome or &gt;3 g/day proteinuria&#xD;
&#xD;
          -  Allergy or intolerance to omega-3 fatty acids, ethyl esters, or fish; known&#xD;
             lipoprotein lipase impairment or deficiency or apoC-II deficiency or familial&#xD;
             dysbetalipoproteinemia&#xD;
&#xD;
          -  History of cancer (other than basal cell carcinoma of the skin) in the past 2 years;&#xD;
             and a history or evidence of major and clinically significant disease that could&#xD;
             adversely affect the conduct of the study or patient safety.&#xD;
&#xD;
          -  Use acetylcholinesterase inhibitors or memantine, in the prior 2 months to screening&#xD;
&#xD;
          -  Use of a lipase inhibitor such as Xenical (orlistat)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin C Maki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis Clinical Research, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>TG ≥500 mg/dL and ≤ 2,000 mg/dL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

